- Home
- TNXP vs MTEX Comparison
TNXP vs MTEX Comparison
Compare TNXP & MTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- MTEX
- Stock Information
- Founded
- TNXP 2007
- MTEX 1993
- Country
- TNXP United States
- MTEX United States
- Employees
- TNXP N/A
- MTEX N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- MTEX Medicinal Chemicals and Botanical Products
- Sector
- TNXP Health Care
- MTEX Health Care
- Exchange
- TNXP Nasdaq
- MTEX Nasdaq
- Market Cap
- TNXP 19.5M
- MTEX 23.0M
- IPO Year
- TNXP N/A
- MTEX 1999
- Fundamental
- Price
- TNXP $0.61
- MTEX $11.87
- Analyst Decision
- TNXP Strong Buy
- MTEX
- Analyst Count
- TNXP 2
- MTEX 0
- Target Price
- TNXP $53.50
- MTEX N/A
- AVG Volume (30 Days)
- TNXP 202.5M
- MTEX 6.5K
- Earning Date
- TNXP 11-12-2024
- MTEX 11-12-2024
- Dividend Yield
- TNXP N/A
- MTEX N/A
- EPS Growth
- TNXP N/A
- MTEX N/A
- EPS
- TNXP N/A
- MTEX N/A
- Revenue
- TNXP $11,291,000.00
- MTEX $121,552,000.00
- Revenue This Year
- TNXP $62.53
- MTEX N/A
- Revenue Next Year
- TNXP $26.17
- MTEX N/A
- P/E Ratio
- TNXP N/A
- MTEX N/A
- Revenue Growth
- TNXP 183.05
- MTEX N/A
- 52 Week Low
- TNXP $0.12
- MTEX $6.75
- 52 Week High
- TNXP $14.08
- MTEX $13.00
- Technical
- Relative Strength Index (RSI)
- TNXP 75.02
- MTEX 61.96
- Support Level
- TNXP $0.32
- MTEX $11.13
- Resistance Level
- TNXP $0.72
- MTEX $12.40
- Average True Range (ATR)
- TNXP 0.15
- MTEX 0.84
- MACD
- TNXP 0.04
- MTEX 0.06
- Stochastic Oscillator
- TNXP 39.61
- MTEX 74.89
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.